Upsher-Smith Laboratories, Inc.
14905 23rd Avenue North
Minneapolis
Minnesota
55447
United States
Tel: 800-328-3344
Website: http://www.upsher-smith.com/
211 articles about Upsher-Smith Laboratories, Inc.
-
Upsher-Smith and the National Alliance of State Pharmacy Associations (NASPA) Announce Excellence in Innovation Award Recipients
2/6/2024
Upsher-Smith Laboratories, LLC and the National Alliance of State Pharmacy Associations proudly announce the recipients of the 2023 NASPA Excellence in Innovation Award.
-
Taiwanese contract development and manufacturing organization Bora will purchase Minnesota-based Upsher-Smith Laboratories, expanding operations into the U.S. for the first time.
-
UPSHER-SMITH LAUNCHES PITAVASTATIN TABLETS
11/6/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Pitavastatin Tablets in 1 mg, 2 mg, and 4 mg strengths.
-
UPSHER-SMITH EXPANDS GENERICS PORTFOLIO WITH LAUNCH OF MESALAMINE EXTENDED-RELEASE CAPSULES, USP
8/21/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Mesalamine Extended-Release Capsules, USP 375 mg.
-
UPSHER-SMITH LAUNCHES FAMOTIDINE FOR ORAL SUSPENSION, USP
8/15/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Famotidine for Oral Suspension, USP.
-
UPSHER-SMITH LAUNCHES ISOTRETINOIN CAPSULES, USP
7/24/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the recent launch of Isotretinoin Capsules, USP in 10 mg, 20 mg, 30 mg, and 40 mg strengths.
-
Upsher-Smith Divests Two Migraine Products
6/26/2023
Upsher-Smith Laboratories, LLC announced that it has entered into a definitive agreement under which New Jersey-based Tonix Pharmaceuticals Holding Corp. and its wholly owned subsidiary Tonix Medicines, Inc. have acquired Zembrace® SymTouch® 3 mg and Tosymra® 10 mg.
-
Tonix Pharmaceuticals Enters into Agreement to Acquire Two FDA-Approved, Marketed Migraine Products from Upsher-Smith Laboratories, LLC
6/26/2023
Tonix Pharmaceuticals Holding Corp. today announced that they have entered into an agreement to acquire two currently-marketed products from Upsher-Smith Laboratories, LLC (Upsher-Smith): Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg. Zembrace SymTouch and Tosymra are both indicated for the treatment of acute migraine with or without aura in adults.
-
UPSHER-SMITH ADDS DICYCLOMINE HYDROCHLORIDE CAPSULES, USP TO ITS PRODUCT LINE
5/16/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Dicyclomine Hydrochloride Capsules, USP 10 mg.
-
UPSHER-SMITH EXPANDS OPHTHALMIC PORTFOLIO WITH LAUNCH OF BRIMONIDINE TARTRATE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION
4/13/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced it has expanded its ophthalmic portfolio with the launch of Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%/0.5%, an AB-rated generic equivalent to the branded product Combigan®.*
-
Upsher-Smith's Becky Jansen Selected as a 2023 Notable Women in Stem Honoree by Twin Cities Business
4/11/2023
Upsher-Smith Laboratories, LLC announced that Becky Jansen, Associate Vice President of Technical Services was recognized as a 2023 Notable Woman in STEM by Twin Cities Business.
-
UPSHER-SMITH LAUNCHES FLUPHENAZINE HYDROCHLORIDE TABLETS
4/3/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluphenazine Hydrochloride Tablets, USP in 1 mg, 2.5 mg, 5 mg, and 10 mg strengths.
-
UPSHER-SMITH RECEIVES TWIN CITIES BUSINESS MANUFACTURING EXCELLENCE AWARD
3/13/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) was one of six Minnesota manufacturers recognized by Twin Cities Business as a 2023 recipient of its Manufacturing Excellence Award.
-
UPSHER-SMITH LAUNCHES DICYCLOMINE HYDROCHLORIDE TABLETS
3/6/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Dicyclomine Hydrochloride Tablets, USP 20 mg.
-
UPSHER-SMITH EXPANDS FLUOXETINE PRODUCT LINE TO INCLUDE AN ORAL SOLUTION
1/26/2023
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has expanded its fluoxetine product family with the launch of Fluoxetine Oral Solution, USP, 20 mg/5 mL.
-
UPSHER-SMITH EXPANDS HALOPERIDOL PRODUCT FAMILY TO INCLUDE UNIT DOSE TABLETS
11/7/2022
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has extended its line of Haloperidol Tablets, USP and is now offering unit dose packaging in 1 mg, 5 mg, and 10 mg strengths.
-
Upsher-Smith Wins Prestigious Diana Award From HDA
6/8/2022
Upsher-Smith Laboratories, LLC announced that it has been honored with a Distribution Industry Award for Notable Achievement in Healthcare for "Best Overall Branded Pharmaceutical Product Manufacturer with less than $300M in sales" by the Healthcare Distribution Alliance.
-
Upsher-Smith Partners With Cove To Expand Access To Its Migraine Medication Tosymra® (Sumatriptan Nasal Spray) 10 mg
9/14/2021
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced its partnership with Cove, a telemedicine company focused entirely on migraine.
-
Upsher-Smith Launches Carbamazepine Extended-Release Tablets, USP
8/16/2021
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Carbamazepine Extended-Release Tablets, USP in 100 mg, 200 mg and 400 mg strengths.
-
Upsher-Smith Launches Isotretinoin Capsules
6/25/2021
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Isotretinoin Capsules.